Credit Suisse initiates coverage of 23andMe at outperform, says stock can rise 78%

Published Tue, Aug 17 20217:23 AM EDTUpdated Tue, Aug 17 202110:50 AM EDT

Jesse Pound @/in/jesse-pound @jesserpound

Anne Wojcicki, 23andMe co-founder & CEO (right) celebrates with 23andMe employees after remotely ringing the NASDAQ opening bell at the headquarters of DNA tech company 23andMe in Sunnyvale, California, U.S., June 17, 2021.

Peter DaSilva | Reuters

The health care potential of genetics company 23andMe should give investors a massive return, according to Credit Suisse.

More In Analyst Calls

Apple is about to jump into the AI race. Here's what analysts expect it to do

Hakyung Kim

This rare muscle disease play can rally more than 50%, BofA says

Alex Harring

Here are Friday's biggest analyst calls: Apple, Target, Coinbase, Berkshire Hathaway, Estee Lauder & more

Michael Bloom